136 related articles for article (PubMed ID: 28435646)
1. Osteosclerosis Secondary to Metastatic Oligodendroglioma.
Maloney PR; Yamaki VN; Kumar R; Johnson D; Hunt C; Jentoft ME; Clarke M
Rare Tumors; 2017 Mar; 9(1):6837. PubMed ID: 28435646
[TBL] [Abstract][Full Text] [Related]
2. Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.
Yasuda T; Nitta M; Komori T; Kobayashi T; Masui K; Maruyama T; Sawada T; Muragaki Y; Kawamata T
Neuropathology; 2018 Feb; 38(1):41-46. PubMed ID: 28812310
[TBL] [Abstract][Full Text] [Related]
3. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
[TBL] [Abstract][Full Text] [Related]
5. Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report.
Burgy M; Chenard MP; Noël G; Bourahla K; Schott R
J Med Case Rep; 2019 Jun; 13(1):202. PubMed ID: 31248444
[TBL] [Abstract][Full Text] [Related]
6. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
7. Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report.
Strickland BA; Cachia D; Jalali A; Cykowski MD; Penas-Prado M; Langford LA; Li J; Shah K; Weinberg JS
Neurosurgery; 2016 Mar; 78(3):E466-73. PubMed ID: 26352098
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic oligodendroglioma metastasizing to the bone marrow: a unique case report and literature review.
Singh VK; Singh S; Bhupalam L
Int J Neurosci; 2019 Jul; 129(7):722-728. PubMed ID: 30526175
[TBL] [Abstract][Full Text] [Related]
9. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
10. Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report.
Demeulenaere M; Duerinck J; DU Four S; Fostier K; Michotte A; Neyns B
Anticancer Res; 2016 Aug; 36(8):4145-9. PubMed ID: 27466523
[TBL] [Abstract][Full Text] [Related]
11. Oligodendrogliomas: new insights from the genetics and perspectives.
Alentorn A; Sanson M; Idbaih A
Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
[TBL] [Abstract][Full Text] [Related]
12. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
Sathornsumetee S; Cheunsuchon P; Sangruchi T
World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
[TBL] [Abstract][Full Text] [Related]
13. Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion.
Gladitz J; Klink B; Seifert M
Acta Neuropathol Commun; 2018 Jun; 6(1):49. PubMed ID: 29890994
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.
Li J; Miao N; Liu M; Cui W; Liu X; Li X; Shi X; Qing S; Ma Y; Zhang W; Biekemituofu H
Int J Clin Exp Pathol; 2014; 7(12):8609-15. PubMed ID: 25674225
[TBL] [Abstract][Full Text] [Related]
16. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
[TBL] [Abstract][Full Text] [Related]
17. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.
Godfraind C; Rousseau E; Ruchoux MM; Scaravilli F; Vikkula M
Neuropathol Appl Neurobiol; 2003 Oct; 29(5):462-71. PubMed ID: 14507338
[TBL] [Abstract][Full Text] [Related]
18. MR textural analysis on T
Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
[TBL] [Abstract][Full Text] [Related]
19. Oligodendrogliomas: molecular biology and treatment.
Bromberg JE; van den Bent MJ
Oncologist; 2009 Feb; 14(2):155-63. PubMed ID: 19182242
[TBL] [Abstract][Full Text] [Related]
20. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]